Personalized Hypoparathyroidism Treatment Systems
Legal Citation
Summary of the Inventive Concept
The present invention discloses a next-generation approach to treating hypoparathyroidism, integrating AI-driven dosing regimens, wearable devices, and nanoparticle-based delivery systems to provide personalized, real-time treatment tailored to individual patients' needs.
Background and Problem Solved
Hypoparathyroidism, a rare endocrine disorder, is currently treated with PTH compounds exhibiting peak-to-trough ratios of less than 4. However, existing treatments lack personalized dosing, real-time monitoring, and targeted delivery, resulting in suboptimal outcomes. The present invention addresses these limitations by envisioning a paradigm shift in hypoparathyroidism treatment.
Detailed Description of the Inventive Concept
The inventive concept comprises a wearable device that administers PTH compounds with a peak-to-trough ratio of less than 4, accompanied by an AI-powered algorithm that adjusts dosing based on the patient's real-time physiological response. Additionally, a nanoparticle-based delivery system targets specific parathyroid hormone receptors, enhancing efficacy and reducing side effects. A biosensor-enabled implantable device continuously monitors parathyroid hormone levels and adjusts PTH compound release accordingly, providing real-time feedback and personalized treatment. A cloud-based platform integrates data from wearable devices, electronic health records, and genomic analysis to optimize treatment outcomes.
Novelty and Inventive Step
The inventive concept's novelty lies in its integration of AI-driven dosing, wearable devices, and nanoparticle-based delivery systems, which provides a personalized, real-time treatment approach that surpasses the limitations of existing PTH compound treatments. The inventive step resides in the synergy of these components, which enables a paradigm shift in hypoparathyroidism treatment.
Alternative Embodiments and Variations
Alternative embodiments may include variations in wearable device designs, AI algorithmic approaches, nanoparticle engineering, and biosensor configurations. Additionally, the inventive concept could be adapted for other endocrine disorders or expanded to incorporate additional data sources, such as environmental or lifestyle factors.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and medical device industries, particularly in the areas of personalized medicine, rare disease treatment, and digital health. The target market includes patients with hypoparathyroidism, as well as healthcare providers and payers seeking more effective and efficient treatment options.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/29 |
| A | A61 | A61K9/00 |
| A | A61 | A61K47/34 |
| A | A61 | A61K47/60 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically endocrine therapeutics and drug delivery systems focusing on parathyroid hormone (PTH) treatment for hypoparathyroidism
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in pharmaceutical sciences, biotechnology, or biomedical engineering, possessing expertise in drug delivery, pharmacokinetics, and medical device design with knowledge of AI and personalized medicine technologies
Obviousness Rationale
A PHOSITA would recognize that the PTD's personalized treatment approach represents a predictable extension of the source patent's core innovation of PTH compound administration with low peak-to-trough ratios. The disclosed AI-driven dosing, wearable devices, and nanoparticle delivery systems are logical technological progressions that apply known personalized medicine techniques to the existing PTH treatment paradigm. These variations represent incremental improvements using standard engineering design choices and well-established technological integration strategies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,603 |
|---|---|
| Title | PTH compounds with low peak-to-trough ratios |
| Assignee(s) | ASCENDIS PHARMA BONE DISEASES A/S |